Literature DB >> 21325067

Large-scale analysis of KIT aberrations in Chinese patients with melanoma.

Yan Kong1, Lu Si, Yanyan Zhu, Xiaowei Xu, Christopher L Corless, Keith T Flaherty, Li Li, Haifu Li, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Siming Li, Mei Han, Lili Mao, Aiping Lu, Jun Guo.   

Abstract

PURPOSE: KIT aberrations were described in acral and mucosal melanomas in largely Caucasian populations. Asian populations are more prone to develop acral and mucosal than cutaneous melanomas, and may harbor a high frequency of KIT aberrations. EXPERIMENTAL
DESIGN: Melanoma subtypes (n = 502) were analyzed histologically to determine melanoma subtype. Tissue samples were analyzed for mutations in exons 9, 11, 13, 17, and 18 of KIT gene in genomic DNA by PCR amplification and Sanger sequencing. The copy numbers of the KIT gene were analyzed by quantitative PCR, and protein expression levels of KIT (CD117) were determined by immunohistochemistry.
RESULTS: The most common melanoma subtypes were acral (38.4%) and mucosal (33.3%) melanomas in this population. The overall incidence of somatic mutations within the KIT gene was 10.8% (54/502), and all subtypes of melanoma contained KIT mutations. Increases in KIT gene copy numbers were correlated to CD117 overexpression. The genetic mutations of KIT were unrelated to the age, gender, stage, thickness, and ulceration of primary melanomas. Importantly, the overall survival of melanoma patients with KIT mutations (P = 0.001) or with KIT aberrations (mutation plus amplification, P = 0.0002) was significantly shorter than that of patients without such alterations.
CONCLUSION: In China, the prevalent melanomas are acral and mucosal melanomas. KIT mutations are detected in all melanoma subtypes. Our study suggests that increases in KIT gene copy numbers, but not KIT mutations, may be correlated to CD117 overexpression. For the first time, our study suggests that genetic KIT aberration is an adverse prognostic factor for melanoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325067     DOI: 10.1158/1078-0432.CCR-10-2346

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  75 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  New strategies in melanoma: molecular testing in advanced disease.

Authors:  Scott E Woodman; Alexander J Lazar; Kenneth D Aldape; Michael A Davies
Journal:  Clin Cancer Res       Date:  2012-01-24       Impact factor: 12.531

Review 3.  Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

Authors:  Jun Guo; Shukui Qin; Jun Liang; Tongyu Lin; Lu Si; Xiaohong Chen; Zhihong Chi; Chuanliang Cui; Nan Du; Yun Fan; Kangsheng Gu; Fang Li; Junling Li; Yongheng Li; Houjie Liang; Jiwei Liu; Man Lu; Aiping Lu; Kejun Nan; Xiaohui Niu; Hongming Pan; Guoxin Ren; Xiubao Ren; Yongqian Shu; Xin Song; Min Tao; Baocheng Wang; Wenbin Wei; Di Wu; Lingying Wu; Aiwen Wu; Xiaolin Xu; Junyi Zhang; Xiaoshi Zhang; Yiping Zhang; Huiyan Zhu
Journal:  Ann Transl Med       Date:  2015-12

Review 4.  Molecular targets in melanoma: time for 'ethnic personalization'.

Authors:  Shane Y Morita; Svetomir N Markovic
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

5.  Analysis of TSC1 mutation spectrum in mucosal melanoma.

Authors:  Meng Ma; Jie Dai; Tianxiao Xu; Sifan Yu; Huan Yu; Huan Tang; Junya Yan; Xiaowen Wu; Jiayi Yu; Zhihong Chi; Lu Si; Chuanliang Cui; Xinan Sheng; Yan Kong; Jun Guo
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-28       Impact factor: 4.553

6.  Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  S Martín-Algarra; M T Fernández-Figueras; J A López-Martín; A Santos-Briz; A Arance; M D Lozano; A Berrocal; J J Ríos-Martín; E Espinosa; J L Rodríguez-Peralto
Journal:  Clin Transl Oncol       Date:  2013-10-16       Impact factor: 3.405

7.  Genotyping of cutaneous melanoma.

Authors:  Isabella C Glitza; Michael A Davies
Journal:  Chin Clin Oncol       Date:  2014-09

8.  Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.

Authors:  Diane Tseng; Julie Kim; Andrea Warrick; Dylan Nelson; Marina Pukay; Carol Beadling; Michael Heinrich; Maria Angelica Selim; Christopher L Corless; Kelly Nelson
Journal:  J Am Acad Dermatol       Date:  2014-05-17       Impact factor: 11.527

9.  Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.

Authors:  Muhammad Khattak; Rosalie Fisher; Samra Turajlic; James Larkin
Journal:  Ther Adv Med Oncol       Date:  2013-03       Impact factor: 8.168

10.  A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.

Authors:  Chuanliang Cui; Lili Mao; Zhihong Chi; Lu Si; Xinan Sheng; Yan Kong; Siming Li; Bin Lian; Kangsheng Gu; Min Tao; Xin Song; Tongyu Lin; Xiubao Ren; Shukui Qin; Jun Guo
Journal:  Mol Ther       Date:  2013-05-14       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.